Sunday, September 7, 2025

Latest

Canaccord Reiterates Rating On CloudMD After Quarterly Results

On August 25, CloudMD Software & Services (TSXV: DOC) reported their second quarter financial results. The company announced record revenues of $15.7 million, up 461% year over year. Gross profit came in at $5.55 million, up 439% and gross margin was 35.5%. The company lost $6.15 million on the bottom line, resulting in earnings per share of ($0.03.) Adjusted EBITDA meanwhile came in at ($0.72) million.

CloudMD currently has 6 analysts covering the stock with an average 12-month price target of $3.97, or an 112% upside. The street high sits at $5.00 from Stephens Inc, while the lowest comes in at $3.30. Out of the 6 analysts, 2 have strong buy ratings and 4 have buy ratings.

In Canaccord’s note to investors, they reiterated their $3.50 12-month price target and speculative buy rating saying that this quarter showed organic growth and that they expect profits in the third quarter.

CloudMD reported $15.7 million in revenue, higher than the Canaccord $15.3 million estimate and $15.0 million street estimate. Adjusted EBITDA also came in better than expected. Canaccord says that revenue benefitted from partial contributions from its Aspiria, Rx Infinity, VisionPros, and Ocdidium deals closing in the middle of the quarter.

Canaccord says that the company’s 9% sequential organic growth is notable as the company has been in roll-up mode for a long time, so it was hard to get accurate organic growth data. Canaccord adds, “The company has a strong sales pipeline of multi-year engagement opportunities, expecting two additional employers to go live in Q3.” Canaccord does believe that the company has enough cash to execute on any new M&A that comes up, as the company ended the quarter with $61 million in cash, $25 million in debt and $62 million in a credit facility.

Below you can see Canaccord’s updated third quarter, full-year 2021, and 2022 estimates. They have modified their estimates as they expect a more conservative ramp into profitability.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Avino Q2 Earnings: Steady As She Goes

MEG Energy: Cenovus Comes In With $7.9 BILLION Offer

Orla Mining Q2 Earnings: Musselwhite Changes Everything

Recommended

ESGold Outlines $24.3 Million NPV For Tailings Reprocessing Project

First Majestic Encounters 711 g/t Silver Equivalent Over 8.0 Metres In Ongoing Exploration At Los Gatos

Related News

BMO: Kinross Gold’s Russian Operations Expected To Be Closed Until At Least September

On March 2nd, Kinross Gold Corporation (TSX: K) announced the suspension of its Russian operations....

Saturday, March 5, 2022, 01:08:00 PM

Hycroft Mining Cash Infusion Not Near Enough To Re-Enter Production, Says BMO

This week, Hycroft Mining (NASDAQ: HYMC), a busted SPAC mining company taken public by Mudrick...

Thursday, March 17, 2022, 04:52:00 PM

BMO Upgrades AngloGold To Outperform, Raises Price Target To $36

This morning, BMO Capital Markets upgraded AngloGold Ashanti (NYSE: AU) to outperform and upgraded their...

Tuesday, December 8, 2020, 11:34:03 AM

Haywood Cuts Cresco Labs Price Target To $15.50 On Poor Earnings

At the tail end of March, Cresco Labs (CSE: CL) announced its fourth-quarter financial results,...

Sunday, April 3, 2022, 03:09:00 PM

BMO Cuts Roger Communications’ Price Target After Boardroom Drama Flares Up

On October 8th, The Globe and Mail reported on the recent and abrupt departure of...

Sunday, October 17, 2021, 01:07:00 PM